/
Oncology
Papillary Renal Cell Carcinoma
4
Pipeline Programs↗
2
Active Trials↗
3
Companies Involved↗
Papillary Renal Cell Carcinoma is an early-stage landscape with 4 programs across 3 companies. 1 program is in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Pipeline
Programs by Phase
Preclinical
No programs
Phase 1
No programs
Phase 31
Approved
No programs
Analysis
Modality Breakdown
75%
Monoclonal antibody
3 of 4 classified programs — the dominant modality here.
Monoclonal antibody leads; the ring shows all 4 classified programs, each share of the total. Modality classified for 100% of 4 pipeline programs.
Analysis
Trial Status
5
clinical trials
Completed2 · 40%
Not yet recruiting1 · 20%
Terminated1 · 20%
Active, not recruiting1 · 20%
Clinical Trials
Trial Activity
Multi-classifier System for Stratifying Stage III Papillary Renal Cell Carcinoma of Receiving Adjuvant Therapy
Not yet recruiting·FFirst Affiliated Hospital, Sun Yat-Sen University·Phase 3·NCT06146777·468 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)